Latest Global Manufacturing News

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

EcoGraf confirms its patented HFfree process offers competitive costs for producing high-purity spherical graphite, targeting non-Chinese battery supply chains with plans for facilities in the US, Europe, and Asia.

archTIS delivered a 231% year-on-year increase in annual recurring revenue to A$15.1 million, marked by the full deployment of its US Department of Defense custom software and a significant contract with a US-European military alliance.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Orica Limited has resolved its US litigation with CF Industries by agreeing to a US$169.5 million settlement and is acquiring Nelson Brothers’ explosives business, strengthening its North American operations and boosting earnings.

Titomic Limited is planning to redomicile from Australia to the United States, aiming to deepen its footprint in the US defense and aerospace sectors and pursue a US stock exchange listing.

Orica reports solid first-half earnings growth led by digital and specialty chemicals, while launching a $100 million cost reduction program to navigate supply disruptions and litigation headwinds.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Amanda Lacaze, the CEO who transformed Lynas Rare Earths from a struggling startup to an ASX50 powerhouse, has announced her retirement. The company is now searching for a new leader to guide its next growth phase.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.